Surface-engineered milk-derived extracellular vesicles enable oral miRNA therapy against immunosuppressive pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) shows limited responsiveness to conventional therapies due to an immunosuppressive tumor microenvironment (TME) characterized by programmed death-ligand 1 (PD-L1)-mediated immune escape and oncogenic microRNA-21 (miR-21) signaling. Despite the potential of miRNA therapeutics, the...